4HG0 Stock Chart & Stats
€0.25
-€0.01(-8.07%)
At close: 4:00 PM EST
€0.25
-€0.01(-8.07%)
Day’s Range― - ―
52-Week Range€0.09 - €0.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.10M
Enterprise Value€27.25M
Total Cash (Recent Filing)€6.63M
Total Debt (Recent Filing)€8.71M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding28,874,178
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-11.77
Revenue Forecast (FY)€10.82M
Bulls Say, Bears Say
Bulls Say
Platform-based Near-patient DiagnosticsQlife's Egoo Health platform targets at-home and near-patient diagnostics with linked tests and digital follow-up. A platform model supports repeat consumable sales, patient stickiness and data-driven services, aligning with the secular shift to decentralized care and durable demand growth.
Integrated Hardware-software EcosystemThe combination of device, consumable tests and digital follow-up creates an integrated ecosystem that can enable better unit economics and recurring revenue once scale is achieved. Software and data layers offer differentiation and potential long-term margin expansion versus single-product peers.
TTM Equity Turned PositiveMoving from negative to positive trailing equity reduces immediate insolvency risk and marginally improves financing optionality. Sustained positive equity, if maintained, gives a larger buffer to absorb losses and eases access to capital for commercialization and scaling initiatives.
Bears Say
Persistent Negative Cash FlowThe company is burning large amounts of cash on operations and free cash flow, creating a structural funding need. Persistent negative cash generation forces reliance on external financing, increases dilution risk and constrains investment in sales, regulatory clearance and scale-up absent rapid revenue gains.
Minimal And Declining RevenueVery low and falling revenues indicate weak commercial traction and challenge the sustainability of the business model. With revenues far below fixed cost levels, the firm cannot leverage its platform economics and must achieve a material and durable sales inflection to reach positive operating leverage.
High Leverage And Shrinking AssetsHigh debt relative to equity and a shrinking asset base materially reduce financial flexibility. Elevated leverage raises refinancing and interest-rate vulnerability, limits strategic options and elevates the risk that liquidity pressures will force restructuring or disadvantageous funding during ongoing losses.
4HG0 FAQ
What was Qlife Holding AB’s price range in the past 12 months?
Qlife Holding AB lowest stock price was €0.09 and its highest was €0.40 in the past 12 months.
What is Qlife Holding AB’s market cap?
Qlife Holding AB’s market cap is €5.10M.
When is Qlife Holding AB’s upcoming earnings report date?
Qlife Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 20 days.
How were Qlife Holding AB’s earnings last quarter?
Qlife Holding AB released its earnings results on May 13, 2026. The company reported -€0.065 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.065.
Is Qlife Holding AB overvalued?
According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued.
Does Qlife Holding AB pay dividends?
Qlife Holding AB does not currently pay dividends.
What is Qlife Holding AB’s EPS estimate?
Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qlife Holding AB have?
Qlife Holding AB has 28,874,178 shares outstanding.
What happened to Qlife Holding AB’s price movement after its last earnings report?
Qlife Holding AB reported an EPS of -€0.065 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.041%.
Which hedge fund is a major shareholder of Qlife Holding AB?
Currently, no hedge funds are holding shares in DE:4HG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Qlife Holding AB
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.